Epigenetics modifications and therapeutic prospects in human thyroid cancer

Frontiers in Endocrinology

Volumn 3, Issue MAR, 2012, Pages

  Catalano, Maria Graziella ^a   Fortunati, Nicoletta ^b   Boccuzzi, Giuseppe ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b Oncological Endocrinology   (Italy)

Author keywords

Advanced thyroid cancer; Anaplastic thyroid cancer; Demethylating agents; Epigenetic; Histone deacetylase inhibitors; Target therapy

Indexed keywords

EID: 84864255732     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2012.00040     Document Type: Article

References (91)

1. Alvarez-Nuñez, F., Bussaglia, E., Mauri-cio, D., Ybarra, J., Vilar, M., Lerma, E., de Leiva, A., and Matias-Guiu, X. (2006). Thyroid Neoplasia Study Group. PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid 16, 17-23.
2. Anand-Apte, B., Bao, L., Smith, R., Iwata, K., Olsen, B. R., Zetter, B., and Apte, S. S. (1996). A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochem. Cell Biol. 74, 853-862.
3. Atadja, P. (2009). Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 280, 233-241.
4. Baylin, S. B., and Herman, J. G. (2000). DNA hypermethylation in tumori-genesis: epigenetics joins genetics. Trends Genet. 16, 168-174.
5. Blaheta, R. A., Michaelis, M., Driever, P. H., and Cinatl, J. Jr. (2005). Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med. Res. Rev. 25, 383-397.
6. Borbone, E., Troncone, G., Ferraro, A., Jasencakova, Z., Stojic, L., Espos-ito, F., Hornig, N., Fusco, A., and Orlando, V. (2011). Enhancer of zeste homolog 2 overexpres-sion has a role in the development of anaplastic thyroid carcinomas. J. Clin. Endocrinol. Metab. 96, 1029-1038.
7. Braun, J., Hoang-Vu, C., Dralle, H., and Hüttelmaier, S. (2010). Downregula-tion of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene29, 4237-4244.
8. Brest, P., Lassalle, S., Hofman, V., Bor-done, O., Gavric Tanga, V., Bon-netaud, C., Moreilhon, C., Rios, G., Santini, J., Barbry, P., Svanborg, C., Mograbi, B., Mari, B., and Hofman, P. (2011). MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells. Endocr. Relat. Cancer 18, 711-719.
9. Catalano, M. G., Fortunati, N., Pugliese, M., Costantino, L., Poli, R., Bosco, O.,andBoccuzzi,G. (2005). Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J. Clin. Endocrinol. Metab. 90,1383-1389.
10. Catalano, M. G., Fortunati, N., Pugliese, M., Poli, R., Bosco, O., Mastro-cola, R., Aragno, M., and Boccuzzi, G. (2006). Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J. Endocrinol. 191,465-472.
11. Catalano, M. G., Poli, R., Pugliese, M., Fortunati, N., and Boccuzzi, G. (2007). Valproic acid enhances tubulin acetylation and apop-totic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr. Relat. Cancer 14, 839-845.
12. Catalano, M. G., Poli, R., Pugliese, M., Fortunati, N., and Boccuzzi, G. (2010). Emerging molecular therapies of advanced thyroid cancer. Mol. AspectsMed. 31,215-226.
13. Catalano, M. G., Pugliese, M., Gargan-tini, E., Grange, C., Bussolati, B., Asioli, S., Bosco, O., Poli, R., Com-pagnone, A., Bandino, A., Mainini, E, Fortunati, N., and Boccuzzi, G. (2011). Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo. Int. I Cancer 130,694-704.
14. Chakravarty, D., Santos, E., Ryder, M., Knauf, J. A., Liao, X. H., West, B. L., Bollag, G., Kolesnick, R., Thin, T. H., Rosen, N., Zanzonico, P., Larson, S. M., Refetoff, S., Ghossein, R., and Fagin, J. A. (2011). Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J. Clin. Invest. 121, 4700-4711.
15. Chi, P., Allis, C. D., and Wang, G. G. (2010). Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 10, 457-459.
16. Ciampi, R., and Nikiforov, Y. E. (2005). Alterations of the BRAF gene in thyroid tumors. Endocr. Pathol. 16, 163-172.
17. Copland, J. A., Marlow, L. A., Williams, S. F., Grebe, S. K., Gumz, M. L., Maples, W J., Silverman, V. E., and Smallridge, R. C. (2006). Molecular diagnosis of a BRAF papillary thyroid carcinoma with multiple chromosome abnormalities and rare adrenal and hypo-thalamic metastases. Thyroid 16, 1293-1302.
18. Donninger, H., Vos, M. D., and Clark, G. J. (2007). The RASSF1A tumor suppressor. J. Cell Sci. 120, 3163-3172.
19. Duenas-Gonzalez, A., Candelaria, M., Perez-Plascencia, C., Perez-Cardenas, E., de la Cruz-Hernandez, E., and Herrera, L. A. (2008). Valproic acid as epigenetic cancer drug: preclinical, clinical and tran-scriptional effects on solid tumors. Cancer Treat. Rev. 34, 206-222.
20. Durante, C., Puxeddu, E., Ferretti, E., Morisi, R., Moretti, S., Bruno, R., Barbi, F., Avenia, N., Scipioni, A., Verrienti, A., Tosi, E., Cavaliere, A., Gulino, A., Filetti, S., and Russo, D. (2007). BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J. Clin. Endocrinol Metab. 92, 2840-2843.
21. Elisei, R., Shiohara, M., Koeffler, H. P, and Fagin, J. A. (1998). Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. Cancer 83,2185-2193.
22. Ellis, L., Atadja, P. W., and Johnstone, R. W. (2009). Epigenetics in cancer: targeting chromatin modifications. Mol. Cancer. Ther. 8,1409-1420.
23. Fagin, J. A. (2004). How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy.J. Endocrinol. 183, 249-256.
24. Fassnacht,M.,Kreissl, M. C.,Weismann, D., and Allolio, B. (2009). New targets and therapeutic approaches for endocrine malignancies. Pharmacol. Ther. 123, 117-141.
25. Feinberg, A. P., Ohlsson, R., and Henikoff, S. (2006). The epigenetic progenitor origin of human cancer. Nat Rev. Genet. 7, 21-33.
26. Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., and Pavletich, N. P. (1999). Structures of a histone deacetylasehomologue bound to the TSA and SAHA inhibitors. Nature 401, 188-193.
27. Fortunati, N., Catalano, M. G., Arena, K., Brignardello, E., Piovesan, A., and Boccuzzi, G. (2004). Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells. J. Clin. Endocrinol. Metab. 89,1006-1009.
28. Fraga, M. F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., Iyer, N. G., Pérez-Rosado, A., Calvo, E., Lopez, J. A., Cano, A., Calasanz, M. J., Colomer, D., Piris, M. A., Ahn, N., Imhof, A., Caldas, C., Jenuwein, T., and Esteller, M. (2005). Loss of acetylation at Lys16 and trimethy-lation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 37,391-400.
29. Fuino, L., Bali, P., Wittmann, S., Don-apaty, S., Guo, F., Yamaguchi, H., Wang, H. G., Atadja, P., and Bhalla, K. (2003). Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol. Cancer Ther. 2, 971-984.
30. Garcia-Rostan, G., Camp, R. L., Herrero, A., Carcangiu, M. L., Rimm, D. L., and Tallini, G. (2001). Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am. J. Pathol. 158,987-996.
31. Ghossein, R. (2009). Problems and controversies in the histopathology of thyroid carcinomas of follicular cell origin. Arch. Pathol Lab. Med. 133, 683-691.
32. Göttlicher, M., Minucci, S., Zhu, P., Krämer, O. H., Schimpf, A., Giavara, S., Sleeman, J. P., Lo Coco, F., Nervi, C., Pelicci, P. G., and Heinzel, T. (2001). Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBOJ. 17,6969-6978.
33. Graff, J. R., Greenberg, V. E., Herman, J. G., Westra, W. H., Boghaert, E. R., Ain, K. B., Saji, M., Zeiger, M. A., Zimmer, S. G., and Baylin, S. B. (1998). Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma. Cancer Res. 58, 2063-2066.
34. Hoque, M. O., Rosenbaum, E., Westra, W. H., Xing, M., Ladenson, P., Zeiger, M. A., Sidransky, D., and Umbricht, C B. (2005). Quantitative assess ment of promoter methylation pro files in thyroid neoplasms. J. Clin. Endocrinol. Metab. 90,4011-4018.
35. Hu, S., Liu, D. X., Tufano, R. P., Carson, K. A., Rosenbaum, E., Cohen, Y., Holt, E. H., Kiseljak-Vassiliades, K., Rhoden, K. J., Tolaney, S., Con-douris, S., Tallini, G., Westra, W. H., Umbricht, C. B., Zeiger, M. A., Califano, J. A., Vasko, V., and Xing,M. (2006). Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int. J. Cancer. 119, 2322-2329.
36. Imanishi, R., Ohtsuru,A.,Iwamatsu, M., Iioka, T., Namba, H., Seto, S., Yano, K., and Yamashita, S. (2002). A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy. J. Clin. Endocrinol. Metab. 87, 4821-4824.
37. Jo, Y. S., Li, S., Song, J. H., Kwon, K. H., Lee, J. C., Rha, S. Y., Lee, H. J., Sul, J. Y., Kweon, G. R., Ro, H. K., Kim, J. M., and Shong, M. (2006). Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer.J. Clin. Endocrinol. Metab. 91, 3667-3670.
38. Johnstone, R. W. (2002). Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. DrugDiscov. 1,287-299.
39. Jones, P. A., and Baylin, S. B. (2007). The epigenomics of cancer. Cell 128, 683-692.
40. Kelly, W K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., Schwartz, L., Richardson, S., Chu, E., Olgac, S., Marks, P. A., Scher, H., and Richon, V. M. (2005). Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 23,3923-3931.
41. Kilfoy, B. A., Zheng, T., Holford, T. R., Han, X., Ward, M. H., Sjodin, A., Zhang, Y., Bai, Y., Zhu, C., Guo, G. L., Rothman, N., and Zhang, Y. (2009). International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 20,525-531.
42. Kim, T. H., Yoo, Y. H., Kang, D. Y., Suh, H., Park, M. K., Park, K. J., and Kim, S. H. (2009). Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with dox-orubicin, a synthetic chenodeoxy-cholic acid derivative, or lactacystin. Int.J. Oncol. 34,1353-1362.
43. Kitazono, M., Bates, S., Fok, P., Fojo, T., and Blagosklonny, M. V. (2002). The histone deacetylase inhibitor FR901228 (desipep-tide) restores expression and function of pseudo-null p53. Cancer Biol. Ther. 1, 665-668.
44. Kitazono, M.,Robey, R.,Zhan,Z.,Sarlis, N. J., Skarulis, M. C., Aikou, T., Bates, S., and Fojo, T. (2001). Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 86, 3430-3435.
45. Knauf, J. A., Sartor, M. A., Medve-dovic, M., Lundsmith, E., Ryder, M., Salzano, M., Nikiforov, Y E., Giordano, T. J., Ghossein, R. A., and Fagin, J. A. (2011). Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene 30, 3153-3162.
46. Kondo, T., Nakazawa, T., Ma, D., Niu, D., Mochizuki, K., Kawasaki, T., Naka-mura, N., Yamane, T., Kobayashi, M., and Katoh, R. (2009). Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. Lab. Invest. 89, 791-799.
47. Kroll, T. G., Sarraf, P., Pecciarini, L., Chen, C. J., Mueller, E., Spiegelman, B. M., and Fletcher, J. A. (2000). PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 289,1357-1360.
48. Kuo, M. H., and Allis, C. D. (1998). Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 20, 615-626.
49. Kurkjian, C., Kummar, S., and Murgo, A. J. (2008). DNA methylation: its role in cancer development and therapy. Curr. Probl. Cancer 32, 187-235.
50. Lennard, C. M., Patel, A., Wilson, J., Reinhardt, B., Tuman, C., Fenton, C., Blair, E., Francis, G. L., and Tuttle, R. M. (2001). Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 129, 552-558.
51. Luong, Q. T., O'Kelly, J., Braunstein, G. D., Hershman, J. M., and Koeffler, H. P. (2006). Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin. Cancer Res. 12,5570-5577.
52. Matsuyama, A., Shimazu, T., Sum-ida, Y., Saito, A., Yoshimatsu, Y., Seigneurin-Berny, D., Osada, H., Komatsu, Y., Nishino, N., Khochbin, S., Horinouchi, S., and Yoshida, M. (2002). In vivo destabilization of dynamic microtubules by HDAC6-mediateddeacetylation. EMBOJ. 21, 6820-6831.
53. Miasaki, F. Y., Vivaldi, A., Ciampi, R., Agate, L., Collecchi, P., Capo-danno, A., Pinchera, A., and Elisei, R. (2008). Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'-deoxycytidine treatment. J. Endocrinol. Invest. 31, 724-730.
54. Mitsiades, C. S., Poulaki, V., McMul-lan, C., Negri, J., Fanourakis, G., Goudopoulou, A., Richon, V M., Marks, P. A., and Mitsiades, N. (2005). Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clin. Cancer Res. 11, 3958-3965.
55. Nakagawa, M., Oda, Y., Eguchi, T., Aishima, S., Yao,T.,Hosoi, F., Basaki, Y., Ono, M., Kuwano, M., Tanaka, M., and Tsuneyoshi, M. (2007). Expression profile of class I histone deacety-lases in human cancer tissues. Oncol. Rep. 18, 769-774.
56. Nikiforova, M. N., Lynch, R. A., Bid-dinger, P. W., Alexander, E. K., Dorn, G. W. II, Tallini, G., Kroll, T. G., and Nikiforov, Y. E. (2003a). RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicu-lar carcinoma. J. Clin. Endocrinol. Metab. 88,2318-2326.
57. Nikiforova, M. N., Kimura, E. T., Gandhi, M., Biddinger, P. W., Knauf, J. A., Basolo, F., Zhu, Z., Giannini, R., Salvatore, G., Fusco, A., San-toro, M., Fagin, J. A., and Nikiforov, Y.E. (2003b).BRAFmutations in thyroid tumors are restricted to papillary carcinomas and anaplas-tic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 88, 5399-5404.
58. Nikiforova, M. N., Tseng, G. C., Steward, D., Diorio, D., and Nikiforov, Y. E. (2008). MicroRNA expression profiling of thyroid tumors: biological significance and 550 diagnostic utility. J. Clin. Endocrinol. Metab. 93, 1600-1608.
59. Noguchi, H., Yamashita, H., Murakami, T., Hirai, K., Noguchi, Y., Maruta, J., Yokoi, T., and Noguchi, S. (2009). Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery. Endocr. J. 56, 245-249.
60. Nucera, C., Lawler, J., and Parangi, S. (2011). BRAF(V600E) and microen-vironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res. 71,2417-2422.
61. Nucera, C., Porrello, A., Antonello, Z. A., Mekel, M., Nehs, M. A., Giordano, T. J., Gerald, D., Benjamin, L. E., Priolo, C., Puxeddu, E., Finn, S., Jarzab, B., Hodin, R. A., Pontecorvi, A., Nose, V., Lawler, J., and Parangi, S. (2010).B-Raf(V600E)andthrom-bospondin-1 promote thyroid cancer progression. Proc. Natl. Acad. Sci. U.S.A. 107, 10649-10654.
62. Patel, K. N., and Shaha, A. R. (2006). Poorly differentiated and anaplastic thyroid cancer. Cancer Control 13, 119-128.
63. Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., and Klein, P. S. (2001). Histone deacety-lase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276, 36734-36741.
64. Plumb, J. A., Finn, P. W., Williams, R. J., Bandara, M. J., Romero, M. R., Watkins, C. J., La Thangue, N. B., and Brown, R. (2003). Pharmaco-dynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitorPXD101.Mol. CancerTher. 2,721-728.
65. Provenzano, M. J., Fitzgerald, M. P., Krager, K., and Domann, F. E. (2007). Increase iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC). Otolaryngol. Head Neck Surg. 137, 722-728.
66. Puppin, C., Passon, N., Lavarone, E., Di Loreto, C., Frasca, F., Vella, V., Vigneri,R.,andDamante, G. (2011). Levels of histone acetylation in thyroid tumors. Biochem. Biophys. Res. Commun. 411, 679-83.
67. Roman,S., Lin, R.,andSosa,J. A. (2006). Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107,2134-2142.
68. Santoro, M., Carlomagno, F., Romano, A., Bottaro, D. P., Dathan, N. A., Grieco, M., Fusco, A., Vecchio, G., Matoskova, B., Kraus, M. H., et al. (1995). Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267, 381-383.
69. Sassa, M., Hayashi, Y., Watanabe, R., Kikumori, T., Imai, T., Kurebayashi, J., Kiuchi, T., and Murata, Y. (2011). Aberrant promoter methylation in overexpression of CITED 1 in papillary thyroid cancer. Thyroid 21, 511-517.
70. Sawan, C., Vaissière, T., Murr, R., and Herceg,Z. (2008). Epigenetic drivers and genetic passengers on the road to cancer. Mutat. Res. 642,1-13.
71. Schagdarsurengin, U., Gimm, O., Hoang-Vu, C., Dralle, H., Pfeifer, G. P., and Dammann, R. (2002). Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res. 62,3698-3701.
72. Schweppe, R. E., Klopper, J. P., Korch, C., Pugazhenthi, U., Benezra, M., Knauf, J. A., Fagin, J. A., Mar-low, L. A., Copland, J. A., Small-ridge, R. C., and Haugen, B. R. (2008). Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J. Clin. Endocrinol. Metab. 93, 4331-4341.
73. Sharma, S., Kelly, T. K., and Jones, P. A. (2010). Epigenetics in cancer. Carcinogenesis 31, 27-36.
74. Shen, W. T., Wong, T. S., Chung, W. Y., Wong, M. G., Kebebew, E., Duh, Q. Y., and Clark, O. H. (2005). Valproic acid inhibits growth, induces apop-tosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells. Surgery 138, 979-984.
75. Sherman, S. I. (2010). Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin. Oncol. (R. Coll. Radiol.) 22, 464-468.
76. Sherman, S. I. (2011). Targeted therapies for thyroid tumors. Mod. Pathol. 24, S44-S52.
77. Smallridge, R. C., Marlow, L. A., and Copland, J. A. (2009). Anaplastic thyroid cancer: molecular pathogen-esis and emerging therapies. Endocr. Relat. Cancer 16,17-44.
78. Smith, B. D., Smith, G. L., Hurria, A., Hortobagyi, G. N., and Buchholz, T. A. (2009). Future of cancer incidence in the United States: burdens upon an aging, changing nation. J. Clin. Oncol. 27, 2758-2765.
79. Sterner, D. E., and Berger, S. L. (2000). Acetylation of histones and transcription-related factors. Micro-biol. Mol. Biol. Rev. 64, 435-459.
80. Tuncel, M., Aydin, D., Yaman, E., Taze-bay, U. H., Güç, D., Dogan, A. L., Tas-basan, B., and Ugur, O. (2007). The comparative effects of gene modulators on thyroid specific genes and radioiodine uptake. Cancer Biother. Radiopharm 22, 281-288.
81. Venkataraman, G. M., Yatin, M., Marcinek, R., and Ain, K. B. (1999). Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human NaC/IK symporter gene methylation status. J. Clin. Endocrinol. Metab. 84, 2449-2457.
82. Vivaldi, A., Miasaki, F. Y., Ciampi, R., Agate, L., Collecchi, P., Capodanno, A., Pinchera, A., and Elisei, R. (2009). Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-20-deoxycytidine and retinoic acid. Mol. Cell. Endocrinol. 307, 142-148.
83. Waddington, C. H. (1942). The epigenotype. Endeavour 1, 18-20.
84. Wiseman, S. M., Masoudi, H., Niblock, P., Turbin, D., Rajput, A., Hay, J., Filipenko, D., Huntsman, D., and Gilks, B. (2006). Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am. J. Surg. 191,581-587.
85. Woyach, J. A., Kloos, R. T., Ringel, M. D., Arbogast, D., Collamore, M., Zwiebel, J. A., Grever, M., Villalona-Calero, M., and Shah, M. H. (2009). Lack of therapeutic effect of the histone deacetylase inhibitor vorino-stat in patients with metastatic radioiodine-refractory thyroid carcinoma. J. Clin. Endocrinol. Metab. 94, 164-170.
86. Wreesmann, V B., and Singh, B. (2008). Clinical impact of molecular analysis on thyroid cancer management. Surg. Oncol. Clin. N. Am. 17, 1-35.
87. Xing, M. (2007a). BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr. Rev. 28, 742-762.
88. Xing, M. (2007b). Gene methylation in thyroid tumorigenesis. Endocrinology 148, 948-953.
89. Xing, M., Westra, W H., Tufano, R. P., Cohen, Y., Rosenbaum, E., Rhoden, K. J., Carson, K. A., Vasko, V., Larin, A., Tallini, G., Tolaney, S., Holt, E. H., Hui, P., Umbricht, C. B., Basaria, S., Ewertz, M., Tufaro, A. P., Cal-ifano, J. A., Ringel, M. D., Zeiger, M. A., Sidransky, D., and Laden-son, P. W (2003). Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res. 63, 2316-2321.
90. Zhang, Y., Li, N., Caron, C., Matthias, G., Hess, D., Khochbin, S., and Matthias, P. (2003). HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 22,1168-1179.
91. Zuo, H., Gandhi, M., Edreira, M. M., Hochbaum, D., Nimgaonkar, V L., Zhang, P., Dipaola, J., Evdokimova, V., Altschuler, D. L., and Nikiforov, Y E. (2010). Downregulation of Rap 1 GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors. Cancer Res. 70, 1389-1397.